← 홈

Antibody · 다발성 골수종

15개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 15개
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
AntibodyJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 8상태 ACTIVE
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE
AntibodystaleJanssenPhase 3

Daratumumab (CT-P44, CT-P44(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab with dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 18.4%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab, thalidomide and dexamethasone)

Relapse and / or Refractory Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSanofiPhase 2

Isatuximab SC-OBDS (Isatuximab SC-OBDS)

Plasma Cell Myeloma Refractory · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED